Literature DB >> 15864746

Polyvalent GalNAcalpha1-->Ser/Thr (Tn) and Galbeta1-->3GalNAcalpha1-->Ser/Thr (T alpha) as the most potent recognition factors involved in Maclura pomifera agglutinin-glycan interactions.

Albert M Wu1.   

Abstract

The agglutinin isolated from the seeds of Maclura pomifera (MPA) recognizes a mucin-type disaccharide sequence, Galbeta1-->3GalNAc (T) on a human erythrocyte membrane. We have utilized the enzyme-linked lectinosorbent assay (ELLSA) and inhibition assay to more systematically analyze the carbohydrate specificity of MPA with glyco-recognition factors and mammalian Gal/GalNAc structural units in lectin-glycoform interactions. From the results, it is concluded that the high densities of polyvalent GalNAcalpha1-->Ser/Thr (Tn) and Galbeta1-->3GalNAcalpha1-->Ser/Thr (T(alpha)) glycotopes in macromolecules are the most critical factors for MPA binding, being on a nanogram basis 2.0 x 10(5), 4.6 x 10(4) and 3.9 x 10(4) more active than monovalent Gal, monomeric T and Tn glycotope, respectively. Other carbohydrate structural units in mammalian glycoconjugates, such as human blood group Sd (a+) related disaccharide (GalNAcbeta1-->4Gal) and Pk/P1 active disaccharide (Galalpha1-->4Gal) were inactive. These results demonstrate that the configurations of carbon-4 and carbon-2 are essential for MPA binding and establish the importance of affinity enhancement by high-density polyvalencies of Tn/T glycotopes in MPA-glycan interactions. The overall binding profile of MPA can be defined in decreasing order as high density of polyvalent Tn/T(alpha) (M.W. > 4.0 x 10(4)) >> Tn-containing glycopeptides (M.W. < 3.0 x 10(3)) > monomeric T/Tn and P (GalNAcbeta1-->3Gal) > GalNAc > Gal >> Man, L: ARA: , D: Fuc and Glc (inactive). Our findings should aid in the selection of this lectin for elucidating functions of carbohydrate chains in life processes and for applications in the biomedical sciences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864746     DOI: 10.1007/s11373-004-8178-4

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  7 in total

1.  Characterization of the secondary binding sites of Maclura pomifera agglutinin by glycan array and crystallographic analyses.

Authors:  Jingwei Huang; Zan Xu; Die Wang; Craig M Ogata; Krzysztof Palczewski; Xavier Lee; N Martin Young
Journal:  Glycobiology       Date:  2010-09-08       Impact factor: 4.313

2.  Changes in glycosylation of human blood plasma chitotriosidase in patients with type 2 diabetes.

Authors:  Ewa Żurawska-Płaksej; Ewa Maria Kratz; Mirosława Ferens-Sieczkowska; Maria Knapik-Kordecka; Agnieszka Piwowar
Journal:  Glycoconj J       Date:  2016-02       Impact factor: 2.916

3.  Differential affinities of Erythrina cristagalli lectin (ECL) toward monosaccharides and polyvalent mammalian structural units.

Authors:  Albert M Wu; June H Wu; Ming-Sung Tsai; Zhangung Yang; Nathan Sharon; Anthony Herp
Journal:  Glycoconj J       Date:  2007-09-06       Impact factor: 2.916

Review 4.  Lectins as tools in glycoconjugate research.

Authors:  Albert M Wu; Elwira Lisowska; Maria Duk; Zhangung Yang
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

Review 5.  Plant Lectins Targeting O-Glycans at the Cell Surface as Tools for Cancer Diagnosis, Prognosis and Therapy.

Authors:  Guillaume Poiroux; Annick Barre; Els J M van Damme; Hervé Benoist; Pierre Rougé
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

Review 6.  The Tn antigen-structural simplicity and biological complexity.

Authors:  Tongzhong Ju; Vivianne I Otto; Richard D Cummings
Journal:  Angew Chem Int Ed Engl       Date:  2011-01-21       Impact factor: 15.336

7.  O-Glycosylation Changes in Serum Immunoglobulin G Are Associated with Inflammation Development in Advanced Endometriosis.

Authors:  Katarzyna Sołkiewicz; Monika Kacperczyk; Hubert Krotkiewski; Marcin Jędryka; Ewa Maria Kratz
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.